Verified ComparisonLast updated: 15 April 2026
CJC-1295 vs Tesamorelin
Both are GHRH analogs targeting growth hormone release. Tesamorelin carries an approved indication for HIV-related lipodystrophy, while CJC-1295 remains investigational.
CJC-1295
GH Releasing
4.3/ 5
A−
Tesamorelin
GH Releasing
4.4/ 5
A
Editor's note
Tesamorelin has an approved indication; CJC-1295 is firmly research-focused.
| Criterion | CJC-1295 | Tesamorelin |
|---|---|---|
| Mechanism | GHRH analog (long-acting) | GHRH analog (approved) |
| Approved indication | None | HIV-related lipodystrophy |
| Half-life | Long with DAC | Short |
| Clinical evidence base | Research literature | Approved-indication trials |
| Regulatory status (AU) | Not approved | Defined indication pathway |
Frequently asked questions
Tesamorelin has an approved indication with established clinical data.
Want to read the full reviews?